AstraZeneca PLC
LSEAstraZeneca heads into the final weeks before its October 30 earnings with one clear signal from within: the Non-Executive Chairman just bought stock in the open market, even as borrowing costs have crept to a six-week high. The insider angle is worth examining closely. Michel Demaré, the company's Non-Executive Chair, purchased 2,500 shares at £121.21 on September 14 — a…
Snapshot as of 20 Sept 2026
AstraZeneca heads into the final weeks before its October 30 earnings with one clear signal from within: the Non-Executive Chairman just bought stock in the open market, even as borrowing costs have crept to a six-week…
AstraZeneca heads into the final week of August having delivered its best weekly performance in months — a 5.7% gain that stands well clear of nearly every large-cap pharma peer and reopens the question of whether the…
AstraZeneca has dropped nearly 14% in a single week to 123.64p — a move that stands out even against a broad pharma sell-off, and that lands with Q2 results just 12 days away. The scale of the decline is the first…
AstraZeneca has clawed back 3.1% this week, but the recovery sits atop a 9.7% monthly decline — and the tension between a stabilising stock and a pipeline that keeps delivering trial wins defines where the name heads…
AstraZeneca enters the first week of May carrying its heaviest monthly loss in years. The stock shed another 4.1% this week to close at 133.3p, dragging its one-month decline to almost 13%, as the sector wrestles with…
AstraZeneca heads into its Q1 2026 results — due before the London open on April 29 — after a choppy month that has left the stock nursing a 5% weekly loss and sitting near GBP 139. The lending market offers little…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for AZN — free to start on ORTEX.
Sign up for free →Open AZN on ORTEX